Advances in Chronic Kidney Disease
Volume 15, Issue 1 , Pages 19-28 , January 2008

Disease Management in Chronic Kidney Disease

  • Anjay Rastogi
    • ,
  • Ariel Linden
    • ,
  • Allen R. Nissenson

      Affiliations

    • Corresponding Author InformationAddress correspondence to Allen R. Nissenson, MD, FACP, David Geffen School of Medicine at UCLA, Department of Medicine, Division of Nephrology, Box 951689, 7-155 Factor Bldg, Los Angeles, CA 90095-1689.

References 

  1. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  2. Nissenson AR, Collins AJ, Dickmeyer J, et al. Medical Advisory Board, RMS Disease Management, Inc. Evaluation of disease-state management of dialysis patients. Am J Kidney Dis. 2001;37:938–944(erratum in Am J Kidney Dis 38:701, 2001)
  3. Licht M, Crooks P, Donald L, et al. Progress in renal disease management: Optimal Renal Care. Nephrol News Issues. 2001;15:21–27
  4. National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis. 2002;39:S1–S266(suppl 1)
  5. Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42:1050–1065
  6. Jungers P, Zingraff J, Page B, et al. Detrimental effects of late referral in patients with chronic renal failure: A case-control study. Kidney Int Suppl. 1993;41:S170–S173
  7. Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: A paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. 1998;31:398–417
  8. Winkelmayer WC, Owen WF, Levin R, et al. A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol. 2003;14:486–492
  9. U.S. Renal Data System . USRDS 2004 annual data report: Atlas of end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD: USRDS; 2005;
  10. St Peter WL, Khan SS, Ebben JP, et al. Chronic kidney disease: The distribution of health care dollars. Kidney Int. 2004;66:313–321
  11. Trivedi HS, Pang MM, Campbell A, et al. Slowing the progression of chronic renal failure: Economic benefits and patients' perspectives. Am J Kidney Dis. 2002;39:721–729
  12. Nissenson AR, Collins AJ, Hurley J, et al. Opportunities for improving the care of patients with chronic renal insufficiency: Current practice patterns. J Am Soc Nephrol. 2001;12:1713–1720
  13. Remuzzi G, Ruggenenti P, Perna A, et al. RENAAL Study Group Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results. J Am Soc Nephrol. 2004;15:3117–3125
  14. Disease Management Association of America. Available at: http://www.dmaa.org/dm_definition.asp. Accessed November 27, 2007
  15. Campbell DT, Stanley JC. Experimental and Quasi-experimental Designs for Research. Chicago, IL: Rand McNally College Publishing; 1966;
  16. Cook TD, Campbell DT. Quasi-experimentation: Design and Analysis Issues for Field Settings. Chicago, IL: Rand McNally College Publishing; 1979;
  17. Shadish SR, Cook TD, Campbell DT. Experimental and Quasi-experimental Designs for Generalized Causal Inference. Boston, MA: Houghton Mifflin; 2002;
  18. Linden A, Adams J, Roberts N. An assessment of the total population approach for evaluating disease management program effectiveness. Dis Manag. 2003;6:93–102
  19. Linden A, Roberts N. A users guide to the disease management literature: Recommendations for reporting and assessing program outcomes. Am J Manag Care. 2005;11:81–90
  20. Linden A. Estimating the effect of regression to the mean in health management programs. Dis Manag Healt Outc. 2007;15:7–12
  21. Linden A, Adams J, Roberts N. Evaluating disease management program effectiveness: An introduction to time series analysis. Dis Manag. 2003;6:243–255
  22. Linden A, Adams J, Roberts N. Evaluating disease management program effectiveness: An introduction to the regression-discontinuity design. J Eval Clin Pract. 2006;12:124–131
  23. Linden A, Adams J, Roberts N. Using propensity scores to construct comparable control groups for disease management program evaluation. Dis Manag Healt Outc. 2005;13:107–127
  24. Linden A, Adams J. Evaluating disease management program effectiveness: an introduction to instrumental variables. J Eval Clin Pract. 2006;12:148–154
  25. Linden A, Adams J, Roberts N. Evaluating disease management program effectiveness: An introduction to survival analysis. Dis Manage. 2004;7:180–190
  26. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992;30:473–483
  27. Rabin R, de Charro F. EQ-5D: A measure of health status from the EuroQol Group. Ann Med. 2001;33:337–343
  28. Public Health Division: Report on the 1997 and 1998 NSW Health Surveys. Sydney, NSW Health Department, 2000. Available at: http://www.health.nsw.gov.au/public-health/hs98/euroqol_intro.htm. Accessed November 27, 2007
  29. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: A new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25:333–341
  30. Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245–1255
  31. Boyer JG, Earp JA. The development of an instrument for assessing the quality of life of people with diabetes. Diabetes-39. Med Care. 1997;35:440–453
  32. Hays RD, Kallich JD, Mapes DL, et al. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994;3:329–338
  33. Linden A. What will it take for disease management to demonstrate a return on investment? New perspectives on an old theme. Am J Manage Care. 2006;12:217–222
  34. Crooks P. The first ESRD managed care demonstration project: A Kaiser Permanente view. Nephrol News Issues. 2003;17:29–3134–5
  35. Reynolds L, Geronemus R. A perspective on the Florida ESRD Demonstration Project. Nephrol News Issues. 2004;18:58, 60, 62
  36. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470
  37. Obrador GT, Ruthazer R, Arora P, et al. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol. 1999;10:1793–1800

 Dr. Nissenson is supported in part by the Richard Rosenthal Dialysis Fund.

PII: S1548-5595(07)00150-4

doi: 10.1053/j.ackd.2007.10.011

Advances in Chronic Kidney Disease
Volume 15, Issue 1 , Pages 19-28 , January 2008

Article Tools

* Image Usage & Resolution